Loading...
•
Dec 31, 2023
ACADIA Q4 2023 Earnings Report
Acadia reported Q4 2023 financial results, achieving revenue growth driven by DAYBUE and NUPLAZID sales, and advancing its pipeline with Phase 3 and Phase 2 trials.
Key Takeaways
Acadia Pharmaceuticals reported a transformational year in 2023, achieving 40% revenue growth driven by the launch of DAYBUE and growth in the NUPLAZID franchise. In the fourth quarter, the company advanced its pipeline with the initiation of Phase 3 and Phase 2 trials and reported net income of $45.8 million.
Total net product sales of $726.4 million for 2023, reflecting 40% revenue growth.
DAYBUE net product sales of $87.1 million for the fourth quarter and $177.2 million for the full year 2023.
NUPLAZID net product sales of $143.9 million for the fourth quarter and $549.2 million for the full year 2023.
Initiated a Phase 3 trial of ACP-101 in Prader-Willi syndrome and a Phase 2/Phase 3 program for ACP-204 in Alzheimer’s disease psychosis in Q4 2023.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia provided full year 2024 financial guidance.
Positive Outlook
- DAYBUE net product sales in the range of $370 to $420 million.
- NUPLAZID net product sales in the range of $560 to $590 million.
- GAAP R&D expense in the range of $305 to $325 million.
- GAAP SG&A expense in the range of $455 to $480 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income